Abstract: A novel group of compounds is disclosed for decorating the surface of synthetic polymeric or tissue derived prostheses to prevent adverse rejection events. The decorating molecules are obtained as derivatives of naturally occurring polysaccharides, derivatized to provide functionally reactive groups at the termini thereof, and the reacting with nucleophilic or other groups on the surface of the prosthesis in a simple one step reaction. Some of these reagents are useful in noncovalent adsorption to polyolefinic or perfluorocarbon based materials. Finally, phospholipids partially substituted with the nonantigenic polysaccharides provide a superior bipolar component for liposome formation.

Abstract: During the purification of pharmaceutical grade crosslinked hemoglobin mixtures of crosslinked and uncrosslinked hemoglobin are heated in the presence of nonstoichiometric amounts of oxygen, resulting in the selective precipitation of the uncrosslinked hemoglobin. After separation of the precipitated uncrosslinked tetramers, the crosslinked hemoglobin remaining in the supernatant is so purified that a further chromatography purification step is unnecessary. This hemoglobin is highly crosslinked absolutely free of chromatography fines, and has a low methemoglobin content.

Abstract: An aqueous solution of cross-linked hemoglobin free of active virus and having a P50 under physiologic conditions of at least 26 mm. Hg. are disclosed.

Abstract: Hemoglobin solutions are purified by heating in the presence of a reducing agent or other deoxygenating conditions such that nonhemoglobin proteins are selectively precipitated and/or virus is inactivated while minimizing hemoglobin loss.

Abstract: Hemoglobin solutions are purified by heating in the presence of a reducing agent or other deoxygenating conditions such that nonhemoglobin proteins are selectively precipitated and/or virus is inactivated while minimizing hemoglobin loss. For example the hemoglobin is heated in the form of deoxyhemoglobin.

Abstract: An additive solution is used to preserve normal red blood cell morphology during storage. The solution comprises a concentration of a nontoxic, physiologically compatible sterol, such as cholesterol, epi-cholesterol, lanosterol, stigmasterol, ergosterol, desmosterol, fucosterol, cholestanol, epi-cholestanol, coprosterol, epi-coprosterol, lathosterol, or campesterol. The sterol is present in a concentration of between approximately 1.0 and 3.0 milligrams per milliliter of whole blood.

Abstract: An additive solution, which can be dispersed in whole blood to enhance preservation of normal red cell morphology during storage, comprises a fatty ester which includes at least two ester linkages comprising fatty hydrocarbon groups of about four to twelve carbon atoms each. The solution can be introduced into the whole blood either at the outset of the storage period or any time during the period in an amount to provide, after its introduction, a concentration of the fatty ester of between 150 and 3,000 micrograms per milliliter of whole blood. When introduced at the outset of storage, morphological changes in the red cells are significantly retarded during the storage period. When introduced at later stages of storage, the solution serves to rejuvenate a significant percentage of red cells which have undergone morphological changes prior to the introduction of the solution.